Australia’s vaccine campaign has accelerated in recent months, but we estimate that the pace of vaccinations would have to double to inoculate the adult population by year-end. Unfortunately, Australia’s overreliance on the AstraZeneca vaccine, whose usage is restricted to those above 60 years of age for medical reasons, means that the vaccine rollout risks stalling over the weeks unless deliveries from Pfizer pick up significantly. With the more contagious delta variant now spreading in Sydney, a full recovery in the hardest-hit sectors of the economy is therefore still some way off.
Become a client to read more
This is premium content that requires an active Capital Economics subscription to view.
Already have an account?
You may already have access to this premium content as part of a paid subscription.
Sign in to read the content in full or get details of how you can access it
Register for free
Sign up for a free account to gain:
- Unlock additional content
- Register for Capital Economics events
- Receive email updates and economist-curated newsletters
- Request a free trial of our services